N-(tert-butoxycarbonyl)-2,6-dimethylpiperidine | 105678-29-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-(tert-butoxycarbonyl)-2,6-dimethylpiperidine
• 英文别名: N-Boc-2,6-dimethylpiperidine；tert-Butyl 2,6-dimethylpiperidine-1-carboxylate
• CAS: 105678-29-3
• 化学式: C₁₂H₂₃NO₂
• 分子量: 213.32
• InChiKey: XFHDOSGLKQJYLP-UHFFFAOYSA-N

物化性质

• 沸点：
  267.1±9.0 °C(Predicted)
• 密度：
  0.949±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P264,P280,P302+P352,P305+P351+P338,P332+P313,P337+P313,P362
• 危险性描述：
  H315,H319

反应信息

• 作为产物：
  描述：

  2-甲基-2-丙基2-吡啶基碳酸酯 、 2,6-二甲基哌啶 以 N,N-二甲基甲酰胺 为溶剂， 反应 36.0h， 以81%的产率得到N-(tert-butoxycarbonyl)-2,6-dimethylpiperidine
  参考文献：
  名称：

  用于胺和氨基酸的丁氧基羰基化和苄氧基羰基化的新型氨基保护试剂

  摘要：

  已经开发了用于胺和氨基酸的叔丁氧基羰基化和苄氧基羰基化的新型氨基保护试剂。叔丁基 2-吡啶基碳酸酯和叔丁基 S-(2-吡啶基) 硫代碳酸酯与各种胺和氨基酸完全反应，以高产率提供 N-Boc 胺和 N-Boc 氨基酸。也发现苄基 2-吡啶基碳酸酯和 O-苄基 S-(2-吡啶基) 硫代碳酸酯在氨基酸的苄氧羰基化中非常有效。

  DOI：

  10.1246/bcsj.58.3570

文献信息

• SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR
  申请人：Baumann Andrew Christian

  公开号：US20060281788A1

  公开（公告）日：2006-12-14

  The invention is directed to a method of inhibiting FLT3 tyrosine kinase activity or expression or reducing FLT3 kinase activity or expression in a cell or a subject comprising the administration of a farnesyl transferase inhibitor and a FLT3 kinase inhibitor selected from compounds of Formula I′: Included within the present invention is both prophylactic and therapeutic methods for treating a subject at risk of (or susceptible to) developing a cell proliferative disorder or a disorder related to FLT3.

  本发明涉及一种抑制FLT3酪氨酸激酶活性或表达或减少细胞或受试者中FLT3激酶活性或表达的方法，包括管理法尼基转移酶抑制剂和从公式I'的化合物中选择的FLT3激酶抑制剂。 本发明包括用于治疗处于发展细胞增殖障碍或与FLT3相关障碍风险（或易感性）的受试者的预防和治疗方法。
• METHOD OF INHIBITING C-KIT KINASE
  申请人：Illig R. Carl

  公开号：US20080051402A1

  公开（公告）日：2008-02-28

  A method of reducing or inhibiting kinase activity of C-KIT in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to C-KIT using a compound of the present invention: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof. The present invention is further directed to methods for treating conditions such as cancers and other cell proliferative disorders.

  本发明提供了一种减少或抑制细胞或主体中C-KIT激酶活性的方法，以及使用本发明的化合物预防或治疗主体中的细胞增殖障碍和/或与C-KIT相关疾病的应用：或其溶剂化物、水合物、互变异构体或药用可接受盐。本发明进一步涉及治疗癌症和其他细胞增殖障碍等条件的方法。
• Thermo-base Generator for Low Temperature Solid-phase Imidation of Poly(amic acid)
  作者：Ken-ichi Fukukawa、Tomohito Ogura、Yuji Shibasaki、Mitsuru Ueda

  DOI：10.1246/cl.2005.1372

  日期：2005.10

  Efficient thermo-base generators (TBGs) which can release an secondary alicyclic amine (e.g. 2,6-dimethylpiperidine; DMP) have been developed for low temperature solid-phase imidation of poly(amic acid) (PAA). Such latent thermo-sensitive catalysts promote thermal imidation of PAA film smoothly up to 200 °C, without the salt formation and storage instability of PAA solution.

  已开发出能够释放次环状胺（例如2,6-二甲基哌啶；DMP）的高效热碱发生器（TBG），用于聚酰胺酸（PAA）的低温固相酰亚胺化。这类潜在的热敏催化剂能促进PAA膜在高达200°C时的热酰亚胺化过程，而不形成盐类并避免PAA溶液的储存不稳定性。
• BASE GENERATOR
  申请人：Eternal Chemical Co., Ltd.

  公开号：US20130172569A1

  公开（公告）日：2013-07-04

  The present invention provides a base generator having the structure of formula (1): wherein R 1 , R 2 , R 3 , R 4 , R 5 , and Y circle around (−)} are defined as in the specification. The base generator of the present invention can be used for imidization of a polyimide precursor, promoting crosslinking of epoxy monomers, or crosslinking of polyurethane or polyurea.

  本发明提供了一种具有公式（1）结构的碱发生器： 其中R1、R2、R3、R4、R5和Ycircle around (−)}如说明书中所定义。本发明的碱发生器可用于聚酰亚胺前体的酰亚胺化，促进环氧单体交联，或聚氨酯或聚脲的交联。
• Inhibitors of c-fms kinase
  申请人：Illig R. Carl

  公开号：US20060189623A1

  公开（公告）日：2006-08-24

  The invention is directed to compounds of Formula I: wherein A, X, R 2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.

  该发明涉及公式I的化合物：其中A，X，R2和W在说明书中阐述，以及其溶剂化物，水合物，互变异构体和药学上可接受的盐，可抑制蛋白酪氨酸激酶，特别是c-fms激酶。本发明还提供了使用公式I的化合物治疗自身免疫性疾病和具有炎症成分的疾病的方法；治疗卵巢癌，子宫癌，乳腺癌，结肠癌，胃癌，毛细胞白血病和非小细胞肺癌的转移；以及治疗疼痛，包括由肿瘤转移或骨关节炎引起的骨骼疼痛，或内脏、炎症和神经性疼痛；以及骨质疏松症，帕吉特病和其他骨吸收介导的疾病，包括关节炎，假体失效，骨溶解性肉瘤，骨髓瘤和转移到骨骼的肿瘤。